New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
10:01 EDTNPSP, ICPT, ENTA, IGTE, PANW, MBWM, GILD, ACHN, GRA, NXPI, KPLUF, GIII, ARCW, VRTUOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARC Group (ARCW) initiated with a Buy at Janney Capital... Achillion (ACHN) initiated with an Outperform at FBR Capital... Enanta (ENTA) initiated with an Outperform at FBR Capital... G-III Apparel (GIII) initiated with a Buy at Wunderlich... Gilead (GILD) initiated with an Outperform at FBR Capital... Intercept (ICPT) initiated with an Underperform at FBR Capital... K+S (KPLUF) initiated with a Sell at Goldman... Mercantile Bank (MBWM) initiated with a Buy at Sandler ONeill... NPS Pharmaceuticals (NPSP) initiated with an Outperform at FBR Capital... NXP Semiconductors (NXPI) initiated with a Buy at Stifel... Palo Alto (PANW) initiated with an Outperform at Imperial Capital... Virtusa (VRTU) initiated with a Buy at Maxim... W.R. Grace (GRA) initiated with a Buy at UBS... iGATE (IGTE) initiated with a Buy at Maxim.
News For ARCW;ACHN;ENTA;GIII;GILD;ICPT;KPLUF;MBWM;NPSP;NXPI;PANW;VRTU;GRA;IGTE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 11, 2014
07:19 EDTPANWBarracuda, Imperva, Palo Alto should be bought, says Pacific Crest
Pacific Crest recommends buying Barracuda (CUDA), Imperva (IMPV), and Palo Alto (PANW), as the firm expects IT security to continue growing strongly. The firm thinks the companies named have compelling margins and free cash flow.
06:10 EDTPANWPalo Alto initiated with an Outperform at Macquarie
Subscribe for More Information
05:56 EDTACHNStocks with implied volatility above IV index mean; GME ACHN
Subscribe for More Information
November 10, 2014
16:44 EDTACHNOn The Fly: Closing Wrap
Subscribe for More Information
16:08 EDTNPSPNPS Pharmaceuticals sees FY14 OpEx $185M-$195M vs. prior view of $180M-$200M
Subscribe for More Information
16:07 EDTNPSPNPS Pharmaceuticals sees FY14 revenue at low end of $100M-$110M range
Subscribe for More Information
16:06 EDTNPSPNPS Pharmaceuticals reports Q3 EPS (2c), consensus 2c
Subscribe for More Information
16:00 EDTGILDOptions Update; November 10, 2014
Subscribe for More Information
15:43 EDTPANWAmerican Petroleum Institute to hold a conference
Subscribe for More Information
15:26 EDTNPSPNotable companies reporting after market close
Subscribe for More Information
14:38 EDTPANWU.S. Postal Service suffered cyberattack, NY Times reports
Subscribe for More Information
12:24 EDTACHNOn The Fly: Midday Wrap
Stocks on Wall Street were modestly higher at midday. The averages opened mixed, but very close to the flat line, and have continued to drift slowly higher from that point. There is little to stand in the way of the marketís drift, as the economic calendar is quiet, the earnings season is winding down, and the most closely watched geopolitical situations are currently status quo. ECONOMIC EVENTS: In the U.S., little of note was on the economic calendar. The Federal Reserve's newly introduced Labor Market Conditions Index was flat at 4 in October. The Fed started updating estimates of the LMCI every month beginning with last month. COMPANY NEWS: Shares of Netflix (NFLX) advanced about 1% after xxx President Barack Obama publicly urged the Federal Communications Commission to implement the "strongest possible rules" to protect net neutrality. In response, Verizon (VZ) said it supports the open Internet and continues to believe that the "light-touch regulatory approach in place for the past two decades has been central to the Internetís success," adding that it believes the reclassification Obama called for would "apply 1930s-era utility regulation to the Internet" and be a "radical reversal of course" that would threaten great harm to an open Internet, competition and innovation." A number of Internet Service Providers, including Comcast (CMCSA), Time Warner Cable (TWC), Charter (CHTR) and Cablevision (CVC), moved lower after Obama weighed in on the hot-button issue. MAJOR MOVERS: Among the notable gainers was Achillion Pharmaceuticals (ACHN), which rose 22% after the company presented data from the ongoing Phase 2 study of its Hepatitis C virus treatment at the Annual Meeting of the American Association for the Study of Liver Diseases, or AASLD. Also higher was Dean Foods (DF), which rose more than 13% after the dairy products distributorís third quarter results, as well as its fourth quarter and full year profit outlook, surpassed analystsí consensus estimates. Among the noteworthy losers was Rayonier (RYN), which dropped 13% after management determined that there was a material weakness in the company's internal controls, restated certain previously made financial statements, and cut its dividend reflecting expectations of reduced cash available for distribution due to lower expected annual harvest levels. INDEXES: Near midday, the Dow was up 18.55, or 0.11%, to 17,592.48, the Nasdaq was up 10.77, or 0.23%, to 4,643.30, and the S&P 500 was up 4.01, or 0.2%, to 2,035.93.
10:17 EDTACHNOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
09:35 EDTACHN, GILDActive equity options trading
Subscribe for More Information
09:20 EDTACHN, GILDOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTGILDGilead rises after Merck presents data on HCV combo
Subscribe for More Information
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.
07:20 EDTGILDGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
November 9, 2014
12:02 EDTACHNAchillion reports 100% SVR12 in a Phase 2 combination study with ACH-3102
Subscribe for More Information
11:56 EDTICPTIntercept announces additional data for OCA in primary biliary cirrhosis
Intercept Pharmaceuticals announced new analyses of data from clinical trials on obeticholic acid, OCA, in patients with primary biliary cirrhosis, PBC. Six posters, including posters with new analyses of data from POISE Ė the first Phase 3 trial in PBC in two decades Ė are being presented at today's poster session at the American Association for the Study of Liver Disease, AASLD, Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR, in development for PBC, nonalcoholic steatohepatitis, NASH, primary sclerosing cholangitis, PSC, and other chronic liver diseases.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use